Alexander Y. Walley, MD

Professor, Medicine

Alexander Walley
801 Massachusetts Ave Crosstown Center

Biography

Dr Walley is Professor of Medicine and an addiction expert at Boston Medical Center and Boston University School of Medicine. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts OEND program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.

Dr Walley is the director of the Boston Medical Center Addiction Medicine Fellowship program, as well as the director the NIDA-funded Fellow Immersion Training program in Addiction Medicine, which trains 5 subspecialty fellows each year to integrate addiction science into their subspecialty research. He provides primary care and addiction medicine consultations in the HIV primary care clinic at Boston University School of Medicine/BMC where he leads the FAST PATH (Facilitated Access to Substance abuse Treatment for Prevention and Treatment of HIV) program. Dr Walley co-founded and provides care on the inpatient addiction consult service at Boston Medical Center, which regularly provides consultation for patients admitted to the hospital who use alcohol and substances. Lastly, Dr Walley has been the medical director of the Massachusetts Opioid Overdose Prevention program since it started in 2007. They have trained and equipped over 100,000 people in the community with naloxone rescue kits, culminating in over 25,000 documented overdose rescues.

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University School of Medicine
  • Courtesy Staff Privileges, Medicine, Boston Medical Center

Education

  • Johns Hopkins University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Harvard College, AB

Classes Taught

  • GMSMS710

Publications

  • Published on 4/1/2022

    Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal Policymakers Should Urgently and Greatly Expand Naloxone Access. Am J Public Health. 2022 Apr; 112(4):558-561. PMID: 35319955.

    Read at: PubMed
  • Published on 3/21/2022

    Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 Mar 21. PMID: 35315148.

    Read at: PubMed
  • Published on 3/21/2022

    Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 Mar 21. PMID: 35315162.

    Read at: PubMed
  • Published on 3/1/2022

    Morgan JR, Quinn EK, Chaisson CE, Ciemins E, Stempniewicz N, White LF, Linas BP, Walley AY, LaRochelle MR. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. Med Care. 2022 03 01; 60(3):256-263. PMID: 35026792.

    Read at: PubMed
  • Published on 3/1/2022

    Kimmel SD, Rosenmoss S, Bearnot B, Weinstein Z, Yan S, Walley AY, Larochelle MR. Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. Health Aff (Millwood). 2022 03; 41(3):434-444. PMID: 35254930.

    Read at: PubMed
  • Published on 3/1/2022

    Jawa R, Rozansky H, Clemens D, Fagan M, Walley AY. Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs: An Opportunity for Change in the Time of COVID-19. J Addict Med. 2022 Mar-Apr 01; 16(2):e70-e72. PMID: 33870955.

    Read at: PubMed
  • Published on 2/10/2022

    Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, Doe-Simkins M, Walley AY, Marshall BDL, Bratberg J, Green TC. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022 Mar; 7(3):e210-e218. PMID: 35151372.

    Read at: PubMed
  • Published on 1/13/2022

    Crable E, Jones DK, Walley AY, Hicks JM, Benintendi A, Drainoni ML. How Do Medicaid Agencies Improve Substance Use Disorder Benefits? Lessons from Three States' 1115 Waiver Experiences. J Health Polit Policy Law. 2022 Jan 13. PMID: 35044466.

    Read at: PubMed
  • Published on 1/6/2022

    Crable EL, Benintendi A, Jones DK, Walley AY, Hicks JM, Drainoni ML. Translating Medicaid policy into practice: policy implementation strategies from three US states' experiences enhancing substance use disorder treatment. Implement Sci. 2022 Jan 06; 17(1):3. PMID: 34991638.

    Read at: PubMed
  • Published on 12/31/2021

    Pollini RA, Ozga JE, Joyce R, Xuan Z, Walley AY. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial. Drug Alcohol Depend. 2022 02 01; 231:109259. PMID: 34998246.

    Read at: PubMed

View 169 more publications: View full profile at BUMC

View all profiles